Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
09/10/2026
Johnson & Johnson reported 2-year data for icotrokinra in plaque PsO (Ref)
Johnson & Johnson reported 2-year Phase 3, ICONIC-LEAD/ NCT06095115 data for ICOTYDE® (icotrokinra; IL-23 receptor antagonist) in patients aged ≥12 years with moderate-to-severe plaque psoriasis (PsO).
Endpoint | Results | Timepoint |
PASI 90 | ≥72% | At Wk 12 |
IGA 0/1 (clear or almost-clear skin) | ≥70% | Sustained from Wk 64 through 112 |
PASI 100 (complete skin clearance) | ≥44% | Sustained from Wk 64 through 112 |
IGA 0 (clear skin) | ≥46% | Sustained from Wk 64 through 112 |
Clinically meaningful improvement in itch | 78% | Sustained from Wk 64 through 112 |
Among PASI90 responders who were withdrawn from icotrokindra at Wk 24, 85% regained PASI 90 response within 24 weeks of retreatment.
Safety through 112 remained consistent with the established profile, with no new safety signals identified.
Alumis reported new Phase 3 data for envudeucitinib in plaque PsO (Ref)
Alumis reported new Phase 3 ONWARD program data for envudeucitinib (oral TYK2 inhibitor) in patients with moderate-to-severe plaque psoriasis.
Endpoint | Results | Time point |
PASI 100 (complete skin clearance) | 54% | AT Wk 48 |
Clear or almost clear scalp skin (ss-PGA 0/1) | Over 80% | At wk 48 |
Clinically meaningful itch reduction | Nearly 80% | Sustained through Wk 48 |
DLQI 0/1 | >70% | Maintained through Wk 48 |
Envudeucitinib was generally well tolerated in the ONWARD program. No new safety signals were observed with long-term exposure in ONWARD3.
Alumis said it remained on track to submit an NDA in Q4 2026.
